Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / INCR
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Intercure Ltd. INCR

6 fiscal years on record · ILS · FY2024 reported · SEC filings only
ILS 238.8M
▼ 32.8% YoY
ILS -67.8M
ILS -71.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

InterCure produces and packages bulk cannabis product at its facilities, harvesting the bloomed flower, trimming excess leaves, drying and curing inflorescences, and packaging the processed inflorescences into bulk quantities. It distributes pharmaceutical-grade cannabis products in Israel, using authorized distributors that are IMC-GDP certified, to all of the pharmacies in Israel that are authorized to distribute cannabis products. It has entered into a distribution agreement with a pharmaceutical distributor in Germany. Its current production operations together can produce up to 10 tons per year. Its production system, wholly owned or operated through partnerships, currently consists of two active facilities in Israel, owned and operated by the Company. InterCure has 13 direct subsidiaries.

Written from the business description in Intercure Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth

ILS 238.8M
Revenue, FY2024 · full 6-year series below
Revenue ILS M Net income ILS M
FY2024 · Revenue 238.8 · Net income -67.8
150.0M300.0M-25.0M-50.0M
201920222024
Compound annual growth
+2.8%
+93.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +93.0% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−30 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -28.1% · Net -30.5%
5%10%-20%-40%-60%
201920212024
ROE
FY2024 · ROE -15.9%
5%-5%-10%-15%
201920212024
Three returns, three denominators.
Gross margin12.7%
Operating margin-28.1%
Net margin-30.5%
EBITDA·

Each ILS of equity lost 16 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow ILS M
FY2024 · FCF -71.3
15.0M30.0M-25.0M-50.0M
201920212024
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsILS 762.6M
EquityILS 397.0M
CashILS 78.3M
Gross debtILS 183.0M
Net debtILS 104.7M
Current ratio1.73×

Net debt stands at 26% of equity.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · ILS

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
INCR, 6-year financial record
Metric 202420232022202120202019
Revenue ILS B0.20.40.40.20.10.0
Operating income ILS B−0.1−0.00.10.0−0.0−0.0
EBITDA ILS B◌◌◌◌◌◌
Income tax ILS B−0.00.00.00.0−0.0−0.0
Net income ILS B−0.1−0.10.00.0−0.0−0.0
Free cash flow ILS B−0.1−0.10.00.0−0.0−0.0
EPS, diluted ILS −1.48−1.360.990.11−1.42−0.25
Dividend / sh ILS ◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−15.9−13.09.41.3−14.0−2.3

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 1 failure · 5 divergences in 29 reconciliationsAUDITED

No fiscal year had a computed check that closed clean. 5 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure5 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image